Johnson & Johnson Tremfya — Percent Change (as a percent) increased by 36.2% to 121.8% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 172.5%, from 44.7% to 121.8%. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage change indicates accelerating demand or successful market expansion, whereas a negative change suggests slowing growth, market saturation, or competitive displacement.
This metric measures the period-over-period growth rate of net sales for a specific pharmaceutical product line. It serv...
Comparable to year-over-year or quarter-over-quarter revenue growth rates for individual blockbuster drugs at peer pharmaceutical firms.
jnj_segment_tremfya_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 119.3% | 127.5% | 186.3% | 122.8% | 80.4% | 101.2% | 29.6% | 70.8% | 79.6% | 83% | 44.7% | 55% | 89.4% | 121.8% |
| QoQ Change | — | +6.9% | +46.1% | -34.1% | -34.5% | +25.9% | -70.8% | +139.2% | +12.4% | +4.3% | -46.1% | +23.0% | +62.5% | +36.2% |
| YoY Change | — | — | — | +2.9% | -36.9% | -45.7% | -75.9% | -11.9% | — | +180.4% | -36.9% | -30.9% | +7.7% | +172.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.